A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 09 Dec 2018 Planned End Date changed from 4 Sep 2021 to 2 Oct 2021.
- 09 Dec 2018 Planned primary completion date changed from 4 Sep 2020 to 2 Oct 2020.
- 16 Oct 2018 Planned number of patients changed from 108 to 80.